Sage Therapeutics, Inc. (SAGE)
Data as of , from SEC Form 4 filings.
See up to 3 months of SAGE. The 7-day demo opens the 1M and 3M ranges and puts SAGE on your watchlist.
Start 7-day demoLatest SAGE insider trades
About Sage Therapeutics, Inc. (SAGE)
Sage Therapeutics, Inc. files with the SEC under CIK 0001597553 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
SAGE Form 4 activity by transaction type, last 90 days
No Form 4 activity for SAGE in the last 90 days.
SAGE insider transactions (Form 4)
3516 Form 4 filings on record, the earliest from Nov 1, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael C. Quirk - Officer | Derivative | Common Stock | 24,999 | - | - | |
| Michael C. Quirk - Officer | Derivative | Common Stock | 7,962 | - | - | |
| Michael C. Quirk - Officer | Derivative | Stock Option (Right to Buy) | 36,000 | - | - | |
| Michael C. Quirk - Officer | Derivative | Stock Option (Right to Buy) | 4,000 | - | - | |
| Jessica Federer | Derivative | Stock Option (Right to Buy) | 21,500 | - | - | |
| Christopher Benecchi - Officer | Derivative | Common Stock | 28,053 | - | - | |
| Christopher Benecchi - Officer | Derivative | Common Stock | 36,375 | - | - | |
| Christopher Benecchi - Officer | Derivative | Stock Option (Right to Buy) | 12,500 | - | - | |
| Christopher Benecchi - Officer | Derivative | Stock Option (Right to Buy) | 40,000 | - | - | |
| Elizabeth A. Barrett | Other | Common Stock | 3,000 | - | - | |
| Elizabeth A. Barrett | Derivative | Stock Option (Right to Buy) | 21,500 | - | - | |
| Gregory L. Shiferman - Officer | Other | Common Stock | 7,215 | - | - | |
| Gregory L. Shiferman - Officer | Derivative | Common Stock | 23,735 | - | - | |
| Gregory L. Shiferman - Officer | Derivative | Stock Option (Right to Buy) | 10,000 | - | - | |
| Gregory L. Shiferman - Officer | Derivative | Stock Option (Right to Buy) | 28,000 | - | - | |
| George Golumbeski | Other | Common Stock | 8,000 | - | - | |
| George Golumbeski | Derivative | Stock Option (Right to Buy) | 13,593 | - | - | |
| George Golumbeski | Derivative | Stock Option (Right to Buy) | 21,500 | - | - | |
| Geno J. Germano | Derivative | Stock Option (Right to Buy) | 21,500 | - | - | |
| Barry E. Greene - Officer | Other | Common Stock | 46,940 | - | - | |
| Barry E. Greene - Officer | Derivative | Common Stock | 53,229 | - | - | |
| Barry E. Greene - Officer | Derivative | Stock Option (Right to Buy) | 174,000 | - | - | |
| James M. Frates | Other | Common Stock | 2,845 | - | - | |
| James M. Frates | Derivative | Stock Option (Right to Buy) | 19,154 | - | - | |
| James M. Frates | Derivative | Stock Option (Right to Buy) | 21,500 | - | - | |
| Michael F. Cola | Derivative | Stock Option (Right to Buy) | 21,500 | - | - | |
| James M. Frates | Grant or award | Stock Option (Right to Buy) | 21,500 | $0.00 | - | |
| Michael F. Cola | Grant or award | Stock Option (Right to Buy) | 21,500 | $0.00 | - | |
| Barry E. Greene - Officer | Grant or award | Common Stock | 19,964 | $0.00 | - | |
| Barry E. Greene - Officer | Tax withholding / forfeiture | Common Stock | 4,862 | $6.91 | $34K | |
| Gregory L. Shiferman - Officer | Tax withholding / forfeiture | Common Stock | 79 | $5.48 | $433 | |
| Christopher Benecchi - Officer | Grant or award | Common Stock | 6,250 | $0.00 | - | |
| Christopher Benecchi - Officer | Grant or award | Stock Option (Right to buy) | 12,500 | $0.00 | - | |
| Gregory L. Shiferman - Officer | Grant or award | Common Stock | 5,000 | $0.00 | - | |
| Gregory L. Shiferman - Officer | Grant or award | Stock Option (Right to buy) | 10,000 | $0.00 | - |
SAGE insider trading FAQ
What is the latest insider trade for SAGE?
Sage Therapeutics, Inc. (SAGE) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-07-31. The full record for SAGE runs to 16 Form 4 filings, the earliest from 2024-11-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SAGE stock?
No insider purchases of SAGE were filed in the last 90 days.
How many insiders are selling SAGE stock?
No insider sales of SAGE were filed in the last 90 days.
Where can I see SAGE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SAGE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael C. Quirk view on EDGAR
- - Jessica Federer view on EDGAR
- - Christopher Benecchi view on EDGAR
- - Elizabeth A. Barrett view on EDGAR
- - Gregory L. Shiferman view on EDGAR
- - George Golumbeski view on EDGAR
- - Geno J. Germano view on EDGAR
- - Barry E. Greene view on EDGAR
- - James M. Frates view on EDGAR
- - Michael F. Cola view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where SAGE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SAGE with a 7-day demo
- SAGE on your watchlist
- Every SAGE Form 4 filing on record
- Up to 3 months of SAGE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
